Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonard P James

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|May 11, 2021
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung CancerJoseph Chen, Ana Ruiz-Garcia, Leonard P James, et al.
Advances in Therapy|December 22, 2019
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsJoseph Chen, Huiping Xu, Sylvester Pawlak, et al.
Advances in Therapy|September 10, 2020
Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsJoseph Chen, Huiping Xu, Sylvester Pawlak, et al.
Radiology|June 30, 2009
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancerBinsheng Zhao, Leonard P James, Chaya S Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard, Binsheng Zhao, Camelia S Sima, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I StudyPasi A Jänne, Alice T Shaw, D Ross Camidge, et al.
Cancer Chemotherapy and Pharmacology|April 5, 2011
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionPaul K Paik, Leonard P James, Gregory J Riely, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 11, 2021
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung CancerJoseph Chen, Ana Ruiz-Garcia, Leonard P James, et al.
Advances in Therapy|December 22, 2019
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsJoseph Chen, Huiping Xu, Sylvester Pawlak, et al.
Advances in Therapy|September 10, 2020
Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy ParticipantsJoseph Chen, Huiping Xu, Sylvester Pawlak, et al.
Radiology|June 30, 2009
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancerBinsheng Zhao, Leonard P James, Chaya S Moskowitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard, Binsheng Zhao, Camelia S Sima, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I StudyPasi A Jänne, Alice T Shaw, D Ross Camidge, et al.
Cancer Chemotherapy and Pharmacology|April 5, 2011
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionPaul K Paik, Leonard P James, Gregory J Riely, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Pageof 1